Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Rhea-AI Summary

Aprea Therapeutics (Nasdaq: APRE), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, has announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The event will be held virtually, featuring:

1. A webcasted presentation by Oren Gilad, Ph.D., President and CEO, at 12:30pm ET.

2. One-on-one meetings with investors throughout the event.

The webcast can be accessed via the conference home page or a direct link, and will be available for replay after the event. Investors interested in arranging meetings with management can contact Lytham Partners or register through the provided link.

DOYLESTOWN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will deliver a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, to take place virtually on Tuesday, October 1, 2024.

Company Webcast

The webcasted presentation will take place at 12:30pm ET on Tuesday, October 1, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2024/ or directly at https://app.webinar.net/REdKpEZ1Nkg. The webcast will also be available for replay following the event.

1x1 Meetings

Management will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg/. 

Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website at https://aprea.com/.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310

FAQ

When is Aprea Therapeutics (APRE) participating in the Lytham Partners Fall 2024 Investor Conference?

Aprea Therapeutics (APRE) is participating in the Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024.

What time is Aprea Therapeutics' (APRE) webcasted presentation at the Lytham Partners conference?

Aprea Therapeutics' (APRE) webcasted presentation is scheduled for 12:30pm ET on Tuesday, October 1, 2024.

How can investors access Aprea Therapeutics' (APRE) webcast at the Lytham Partners conference?

Investors can access Aprea Therapeutics' (APRE) webcast through the conference home page at https://lythampartners.com/fall2024/ or directly at https://app.webinar.net/REdKpEZ1Nkg.

Will Aprea Therapeutics (APRE) be available for one-on-one meetings at the Lytham Partners conference?

Yes, Aprea Therapeutics (APRE) management will be available for virtual one-on-one meetings throughout the Lytham Partners Fall 2024 Investor Conference.

How can investors arrange a meeting with Aprea Therapeutics (APRE) management at the Lytham Partners conference?

Investors can arrange meetings with Aprea Therapeutics (APRE) management by contacting Lytham Partners at 1x1@lythampartners.com or registering at https://lythampartners.com/fall2024invreg/.